| Literature DB >> 31729965 |
Zhongquan Li1, Xia Zhao2, Ang Sheng2, Li Wang3,4.
Abstract
BACKGROUND: Anxiety symptoms are pervasive among elderly populations around the world. The Geriatric Anxiety Inventory (the GAI) has been developed and widely used in screening those suffering from severe symptoms. Although debates about its dimensionality have been mostly resolved by Molde et al. (2019) with bifactor modeling, evidence regarding its measurement invariance across sex and somatic diseases is still missing.Entities:
Keywords: Differential item functioning; Dimensionality; Geriatric anxiety inventory; Mokken scale technique
Mesh:
Year: 2019 PMID: 31729965 PMCID: PMC6858656 DOI: 10.1186/s12877-019-1346-1
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Other socio-demographic and clinical characteristics of the sample
| female | male | total | |
|---|---|---|---|
| Marital status | |||
| Married | 531 (54%) | 445 (46%) | 976 (100%) |
| Unmarried | 2 (40%) | 3 (60%) | 5 (100%) |
| Divorced | 43 (61%) | 27 (39%) | 70 (100%) |
| Widowed | 206 (78%) | 57 (22%) | 263 (100%) |
| Education | |||
| Primary school | 179 (67%) | 88 (33%) | 267 (100%) |
| middle school | 189 (58%) | 135 (42%) | 324 (100%) |
| High school | 140 (56%) | 111 (44%) | 251 (100%) |
| College degree or above | 145 (45%) | 176 (55%) | 321 (100%) |
| Other | 129 (85%) | 22 (15%) | 151 (100%) |
| Somatic diseases | |||
| No diseases | 110 (50%) | 112 (50%) | 222 (100%) |
| At least one diseases | 648 (62%) | 404 (38%) | 1052 (100%) |
| Total | 782 (60%) | 532 (40%) | 1314 (100%) |
Descriptive statistics of the items (upper panel) and the scale (lower panel) for the GAI-CV
| Item | M | SD | Hj | SE | citc |
|---|---|---|---|---|---|
| 1 | 0.15 | 0.35 | 0.464 | 0.029 | 0.541 |
| 2 | 0.16 | 0.37 | 0.443 | 0.030 | 0.501 |
| 3 | 0.09 | 0.28 | 0.591 | 0.028 | 0.689 |
| 4 | 0.11 | 0.32 | 0.518 | 0.028 | 0.631 |
| 5 | 0.08 | 0.28 | 0.579 | 0.030 | 0.666 |
| 6 | 0.17 | 0.37 | 0.585 | 0.026 | 0.661 |
| 7 | 0.12 | 0.33 | 0.590 | 0.024 | 0.723 |
| 8 | 0.18 | 0.39 | 0.622 | 0.026 | 0.677 |
| 9 | 0.18 | 0.38 | 0.641 | 0.024 | 0.717 |
| 10 | 0.11 | 0.31 | 0.618 | 0.023 | 0.753 |
| 11 | 0.13 | 0.34 | 0.607 | 0.023 | 0.741 |
| 12 | 0.13 | 0.33 | 0.429 | 0.030 | 0.514 |
| 13 | 0.11 | 0.32 | 0.575 | 0.025 | 0.704 |
| 14 | 0.07 | 0.26 | 0.535 | 0.035 | 0.590 |
| 15 | 0.05 | 0.23 | 0.630 | 0.037 | 0.620 |
| 16 | 0.08 | 0.27 | 0.585 | 0.030 | 0.671 |
| 17 | 0.04 | 0.18 | 0.747 | 0.033 | 0.589 |
| 18 | 0.06 | 0.23 | 0.477 | 0.042 | 0.474 |
| 19 | 0.06 | 0.24 | 0.644 | 0.032 | 0.664 |
| 20 | 0.11 | 0.32 | 0.564 | 0.025 | 0.691 |
| M | 2.19 | ||||
| SD | 4.18 | ||||
| H | 0.565 | 0.020 | |||
| α | 0.937 | ||||
| λ2 | 0.940 | ||||
| MS | 0.947 |
Note. N = 1314. H Item-scalability coefficient, SE Standard error of item scalability coefficient, citc Corrected item–test correlation, H Total-scalability coefficient, α Cronbach’s alpha, λ Guttman’s lambda-2, MS Molenaar–Sijtsma method
Output of assessment of monotonicity
| Item | #ac | #vi | #zsig | crit |
|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 |
| 2 | 6 | 0 | 0 | 0 |
| 3 | 6 | 0 | 0 | 0 |
| 4 | 6 | 0 | 0 | 0 |
| 5 | 6 | 0 | 0 | 0 |
| 6 | 6 | 0 | 0 | 0 |
| 7 | 6 | 0 | 0 | 0 |
| 8 | 6 | 0 | 0 | 0 |
| 9 | 6 | 0 | 0 | 0 |
| 10 | 6 | 0 | 0 | 0 |
| 11 | 6 | 0 | 0 | 0 |
| 12 | 6 | 1 | 0 | 31 |
| 13 | 6 | 0 | 0 | 0 |
| 14 | 6 | 0 | 0 | 0 |
| 15 | 3 | 0 | 0 | 0 |
| 16 | 6 | 0 | 0 | 0 |
| 17 | 0 | 0 | 0 | 0 |
| 18 | 6 | 0 | 0 | 0 |
| 19 | 6 | 0 | 0 | 0 |
| 20 | 6 | 0 | 0 | 0 |
Note. N = 1314. #ac = number of active pairs that were investigated; #vi = number of violations in which the item is involved; # zsig = number of significant z-values; crit = Crit value
Fig. 1Monotonicity plots of the GAI-CV items
The results of automated item selection procedure
| Results | Item Numbers | |||||
|---|---|---|---|---|---|---|
| Scale 1 | Scale 2 | Scale 3 | Scale 4 | Unscalable | ||
| 0–0.4 | 1: 20 | 1–20 | ||||
| 0.45 | 1: 19 | 1–11, 12–20 | 12 | |||
| 0.5–0.55 | 2:16, 2 | 3–11, 13–17, 19–20 | 12, 18 | 1, 2 | ||
| 0.6 | 2:14, 2 | 3, 5, 6–11, 13, 15–17, 19–20 | 12, 18 | 1, 2, 4, 14 | ||
| 0.65 | 4: 9, 2, 2, 2 | 8–11, 13, 15–17, 19 | 12, 18 | 3, 4 | 6, 7 | 1, 2, 5, 20 |
| 0.7 | 3: 7, 3, 2 | 8–9, 13, 15–17, 19 | 3, 10, 11 | 12, 18 | 1, 2, 4–7, 14, 20 | |
| 0.75 | 4: 4, 2, 2, 2 | 8–9, 17, 19 | 3, 10 | 15, 16 | 12, 18 | 1, 2, 4-7, 11, 13-14, 20 |
| 0.8 | 2: 2, 2 | 9, 17 | 8, 19 | 1–7, 10–16, 18, 20 | ||
| 0.85 | 1: 2 | 9, 17 | 1–8, 10–16, 18–20 | |||
The results of DIF analysis with logistic regression
| Item | Sex | Somatic Disease | ||||||
|---|---|---|---|---|---|---|---|---|
| Statistic | Effect size | Statistic | Effect size | |||||
| 1 | 1.46 | 0.48 | 0.0015 | A | 3.66 | 0.16 | 0.0105 | A |
| 2 | 0.92 | 0.63 | 0.0009 | A | 5.56 | 0.06 | 0.0162 | A |
| 3 | 2.14 | 0.34 | 0.0026 | A | 1.94 | 0.38 | 0.0074 | A |
| 4 | 3.06 | 0.21 | 0.0034 | A | 3.92 | 0.14 | 0.0118 | A |
| 5 | 1.39 | 0.50 | 0.0018 | A | 0.15 | 0.93 | 0.0006 | A |
| 6 | 3.61 | 0.16 | 0.0030 | A | 6.60 | 0.04a | 0.0142 | A |
| 7 | 3.98 | 0.14 | 0.0038 | A | 0.76 | 0.69 | 0.0021 | A |
| 8 | 3.96 | 0.14 | 0.0030 | A | 5.98 | 0.05 | 0.0125 | A |
| 9 | 2.74 | 0.25 | 0.0020 | A | 3.05 | 0.22 | 0.0059 | A |
| 10 | 3.86 | 0.15 | 0.0039 | A | 2.44 | 0.30 | 0.0071 | A |
| 11 | 0.15 | 0.93 | 0.0001 | A | 5.32 | 0.07 | 0.0134 | A |
| 12 | 4.02 | 0.13 | 0.0045 | A | 8.97 | 0.01a | 0.0289 | A |
| 13 | 3.97 | 0.14 | 0.0040 | A | 6.00 | 0.04a | 0.0184 | A |
| 14 | 3.79 | 0.15 | 0.0056 | A | 3.10 | 0.21 | 0.0151 | A |
| 15 | 2.14 | 0.34 | 0.0037 | A | 0.50 | 0.78 | 0.0029 | A |
| 16 | 1.36 | 0.50 | 0.0018 | A | 4.61 | 0.10 | 0.0173 | A |
| 17 | 0.19 | 0.91 | 0.0004 | A | 0.22 | 0.90 | 0.0022 | A |
| 18 | 4.33 | 0.11 | 0.0080 | A | 1.68 | 0.43 | 0.0091 | A |
| 19 | 0.89 | 0.64 | 0.0014 | A | 1.13 | 0.57 | 0.0052 | A |
| 20 | 6.01 | 0.04a | 0.0062 | A | 2.12 | 0.35 | 0.0061 | A |
Note. aindicated significance at 0.05 level. The DIF estimates are classified according to effect size as “A” (negligible effect), “B” (moderate effect), and “C” (large effect”)
Fig. 2Plots of DIF across sex
Fig. 3Plots of DIF across disease groups